Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 1, 2014, Pages 95-101

  Jakobsson, Stina ^a   Bergström, Lisa ^b   Björklund, Fredrik ^c   Jernberg, Tomas ^d   Söderström, Lars ^e   Mooe, Thomas ^a,c  

^a UMEÅ UNIVERSITY   (Sweden)

^b Section of Neurology   (Sweden)

^c ÖSTERSUND HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e Unit of Clinical Research Center   (Sweden)

Author keywords

Diabetes mellitus; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PURINERGIC P2Y12 RECEPTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK REDUCTION;

DIABETES MELLITUS; MYOCARDIAL INFARCTION; STROKE;

AGED; AGED, 80 AND OVER; ASPIRIN; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SURVIVAL RATE; SWEDEN;

EID: 84898712039     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000311     Document Type: Article

References (39)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-321
2. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144
3. Mooe T, Olofsson BO, Stegmayr B, Eriksson P. Ischemic stroke. Impact of a recent myocardial infarction. Stroke. 1999;30:997-1001
4. Wienbergen H, Schiele R, Gitt AK, Schneider S, Heer T, Gottwik M, Gieseler U, Weber MA, Muller CH, Neubaur J, Senges J. Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice: mir and mitra study groups: myocardial infarction registry: maximal individual therapy in acute myocardial infarction. The Am J Cardiol.. 2001;87:782-785, A788
5. Saczynski JS, Spencer FA, Gore JM, Gurwitz JH, Yarzebski J, Lessard D, Goldberg RJ. Twenty-year trends in the incidence of stroke complicating acute myocardial infarction: Worcester Heart Attack Study. Arch Intern Med. 2008;168:2104-2110
6. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Yawn BP, Roger VL. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005;143:785-792
7. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol. 2002;55:654-664
8. Herlitz J, Holm J, Peterson M, Karlson BW, Evander MH, Erhardt L; LoWASA Study Group. Factors associated with development of stroke long-term after myocardial infarction: experiences from the LoWASA trial. J Intern Med. 2005;257:201-207
9. Udell JA, Wang JT, Gladstone DJ, Tu JV. Anticoagulation after anterior myocardial infarction and the risk of stroke. PLoS One. 2010;5:e12150
10. Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, Solomon SD; VALIANT Trial Investigators. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J. 2007;28:685-691
11. Spencer FA, Gore JM, Yarzebski J, Lessard D, Jackson EA, Goldberg RJ. Trends (1986 to 1999) in the incidence and outcomes of in-hospital stroke complicating acute myocardial infarction (The Worcester Heart Attack Study). Am J Cardiol. 2003;92:383-388
12. Budaj A, Flasinska K, Gore JM, Anderson FA Jr, Dabbous OH, Spencer FA, Goldberg RJ, Fox KA; GRACE Investigators. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation. 2005;111:3242-3247
13. Albaker O, Zubaid M, Alsheikh-Ali AA, Rashed W, Alanbaei M, Almahmeed W, Al-Shereiqi SZ, Sulaiman K, Al Qahtani A, Al Suwaidi J; Gulf RACE Investigators. Early stroke following acute myocardial infarction: incidence, predictors and outcome in six Middle-Eastern countries. Cerebrovasc Dis. 2011;32:471-482
14. Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, Lagerqvist B, Lindahl B, Stenestrand U, Wallentin L. The Swedish Web- system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617-1621
15. Stenestrand U, Wallentin L; Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436
16. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583-612
17. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;21:959-969
18. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-2538
19. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450
20. Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial infarction. A population-based study. Stroke. 1997;28:762-767
21. Karlsson F, Modica A, Mooe T. Dynamics of platelet activation in diabetic and non-diabetic subjects during the course of an acute myocardial infarction. Thromb Res. 2007;121:269-273
22. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360
23. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502
24. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST- segment elevation. N Engl J Med. 2005;352:1179-1189
25. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22
27. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718
28. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463
29. Anselmino M, Malmberg K, Ohrvik J, Rydén L; Euro Heart Survey Investigators. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardiovasc Prev Rehabil. 2008;15:216-223
30. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625-628
31. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Isis-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770
32. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Gissi-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71
33. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30:962-969
34. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM; GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med. 2004;164:1457-1463
35. Gitt AK, Schiele R, Wienbergen H, Zeymer U, Schneider S, Gottwik MG, Senges J; MITRA Study. Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study. Acta Diabetol. 2003;40(suppl 2):S343-S347
36. Norhammar A, Lindbäck J, Rydén L, Wallentin L, Stenestrand U; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short- and long- term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart. 2007;93:1577-1583
37. Rasoul S, Ottervanger JP, Timmer JR, Yokota S, de Boer MJ, van 't Hof AW; Zwolle Myocardial Infarction Study Group. Impact of diabetes on outcome in patients with non-ST-elevation myocardial infarction. Eur J Intern Med. 2011;22:89-92
38. Svensson AM, Dellborg M, Abrahamsson P, Karlsson T, Herlitz J, Duval SJ, Berger AK, Luepker RV. The influence of a history of diabetes on treatment and outcome in acute myocardial infarction, during two time periods and in two different countries. Int J Cardiol. 2007;119:319-325
39. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- thrombolysis in myocardial infarction 38. Circulation. 2008;118:1626-1636.